Univariate and multivariate analysis of foreign-born patients with antimicrobial resistant isolates (n=366), Euro-GASP 2010–2014
| Epidemiological and clinical characteristics | Resistant isolates from foreign-born patients | |||||
| No. (%) | Crude OR | Adjusted OR | ||||
| (95% CI) | P value | (95% CI) | P value | |||
| Year of diagnosis (n=704) | 0.21 | – | – | |||
| 2010 | 31/50 (62.0) | 1 | ||||
| 2011 | 66/143 (46.2) | 0.5 (0.2 to 1.0) | 0.05 | |||
| 2012 | 99/183 (54.1) | 0.7 (0.3 to 1.3) | 0.32 | |||
| 2013 | 84/173 (48.6) | 0.5 (0.3 to 1.1) | 0.09 | |||
| 2014 | 86/155 (55.5) | 0.7 (0.3 to 1.4) | 0.41 | |||
| Age (years) (n=701) | 0.25 | – | – | |||
| <25 | 96/177 (54.2) | 0.7 (0.4 to 1.4) | 0.4 | |||
| 25–44 | 231/461 (50.1) | 0.6 (0.3 to 1.1) | 0.13 | |||
| ≥45 | 38/63 (60.3) | 1 | ||||
| Area of origin (n=704) | <0.01 | <0.01 | ||||
| EU/EEA | 118/253 (46.6) | 1 | 1 | |||
| Non-EU/EEA WHO EUR | 72/92 (78.3) | 4.1 (2.3 to 7.1) | <0.01 | 3.2 (1.8 to 5.8) | <0.01 | |
| WHO EMR | 57/83 (68.7) | 2.5 (1.4 to 4.2) | <0.01 | 1.8 (1.1 to 3.3) | 0.02 | |
| WHO AMRO | 68/174 (39.1) | 0.7 (0.4 to 1.0) | 0.12 | 0.7 (0.5 to 1.1) | 0.21 | |
| WHO AFR | 22/55 (40.0) | 0.7 (0.4 to 1.3) | 0.37 | 0.6 (0.3 to 1.2) | 0.17 | |
| WHO SEAR | 14/22 (63.6) | 2.0 (0.8 to 4.9) | 0.13 | 1.9 (0.7 to 5.0) | 0.13 | |
| WHO WPR | 15/25 (60.0) | 1.7 (0.7 to 3.9) | 0.2 | 1.6 (0.7 to 3.9) | 0.23 | |
| Sexual orientation (n=677) | <0.01 | <0.01 | ||||
| Heterosexual females | 29/67 (43.3) | 1.0 (0.6 to 1.7) | 0.94 | 1.0 (0.6 to 1.8) | 0.81 | |
| Heterosexual males | 158/248 (63.7) | 2.3 (1.6 to 3.2) | <0.01 | 1.8 (1.2 to 2.7) | <0.01 | |
| Men who have sex with men | 155/362 (42.8) | 1 | 1 | |||
| Isolation site (n=694) | <0.01 | – | – | |||
| Ano-rectal | 66/164 (40.2) | 1 | ||||
| Urogenital | 268/469 (57.1) | 1.9 (1.3 to 2.8) | <0.01 | |||
| Pharyngeal | 25/61 (41.0) | 1.0 (0.5 to 1.8) | 0.92 | |||
| HIV status (n=555) | Positive | 42/115 (36.5) | 1 | <0.01 | – | – |
| Negative | 223/440 (50.7) | 1.7 (1.1 to 2.7) | ||||
| Previous gonorrhoea (n=425) | Yes | 31/68 (45.6) | 1 | 0.03 | – | – |
| No | 212/357 (59.4) | 1.7 (1.0 to 2.9) | ||||
| Probable country of infection (n=319) | Reporting country | 162/286 (56.6) | 1 | 0.66 | – | – |
| Other country | 20/33 (60.6) | 1.1 (0.5 to 2.4) | ||||
EEA, European Economic Area; EU, European Union; Euro-GASP, European Gonococcal Antimicrobial Surveillance Programme; WHO AFR, WHO African Region; WHO AMRO, WHO Region of the Americas; WHO EMR, WHO Eastern Mediterranean Region; WHO SEAR, WHO South-East Asia Region; WHO WPR, WHO Western Pacific Region.